Sanofi has moved quickly to tie up a deal with Ablynx for $4.8 billion, when it looked more likely that Novo Nordisk would wear down the biotech’s resistance with repeated bids. Novo’s loss is Sanofi’s gain, as the latter company has come racing out of the M&A blocks in January – having sealed a major acquisition only a week prior.
Sanofi swoops for Ablynx in $4.8bn deal
